Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11351 - 11375 of 11972 in total
Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent …
PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Investigational
Matched Description: … PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose …
Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common...
Investigational
Matched Description: … Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a ... It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis …
PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in...
Investigational
Matched Description: … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. ... When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle …
99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in...
Investigational
Matched Description: … 99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging …
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found ... The recruitment of macrophages to the arterial wall is believed to be a critical step in the development …
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. ... however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a
An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Experimental
Matched Description: … An amino alcohol with a long unsaturated hydrocarbon chain. …
Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Investigational
Matched Description: … Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel …
SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
Investigational
Matched Description: … SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the …
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
Matched Description: … KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for …
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Experimental
Matched Description: … CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in …
Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study).
Investigational
Matched Description: … Delpazolid (LCB01-0371) is under investigation in clinical trial NCT01554995 (A Clinical Study, Randomized …
Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase .
Experimental
Matched Description: … Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- …
2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).
Investigational
Matched Description: … 2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients …
Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).
Investigational
Matched Description: … Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular …
Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
Investigational
Matched Description: … Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds …
Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).
Investigational
Matched Description: … Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution …
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
Matched Description: … SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex ... B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a
CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. In addition, unlike currently marketed opioids, CR665 does...
Investigational
Matched Description: … Preclinical animal studies suggest that CR665 is a potent analgesic compound. ... CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid …
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It has been well established in the treatment of confusion, anxiety, restlessness (particularly in...
Investigational
Matched Description: … Melperone has been used for a span of greater than 30 years in the European Union [L1316]. ... Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. …
Displaying drugs 11351 - 11375 of 11972 in total